LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$30.48 USD
+1.15 (3.92%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $30.47 -0.01 (-0.03%) 6:12 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LENZ 30.48 +1.15(3.92%)
Will LENZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LENZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LENZ
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?
LENZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect?
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know
Other News for LENZ
Lenz Therapeutics (LENZ) Shares Cross Below 200 DMA
Lenz Therapeutics (LENZ) Target Price Hiked Following FDA Approval
Lenz Therapeutics price target raised by $9 at BofA, here's why
Lenz Therapeutics (LENZ) Sees Raised Price Target After FDA Approval
Lenz Therapeutics price target raised by $8 at H.C. Wainwright, here's why